Bruce E. Johnson, MD

home / authors / bruce-e-johnson-md

Articles

Autocrine Growth Factors and Neuroendocrine Markers in the Development of Small-Cell Lung Cancer

Bruce E. Johnson, MD;Michael J. Kelley, MD

January 2nd 1997

Two different clinical trials using biological agents directed against an autocrine growth factor and a surface marker of neuroendocrine differentiation have been used for patients with relapsed small-cell lung cancer. In a

Multidisciplinary Approach to Potentially Curable Non-Small Cell Carcinoma of the Lung

Bruce E. Johnson, MD

January 1st 1997

The treatment of potentially curable non-small-cell lung cancer (NSCLC) is currently evolving. Drs. Greco and Hainsworth provide information about the potential use of chemotherapy, radiation, and surgery in patients with stage IB-IV NSCLC. The authors have taken on the challenging task of summarizing recent clinical research, referencing current clinical studies, and providing some predictions on the outcomes of ongoing clinical investigation.

Commentary (Johnson): Integration of Vinorelbine into Chemotherapy Strategies for Non-Small-Cell Lung Cancer

Bruce E. Johnson, MD

June 1st 1995

Dr. Vokes provides information about integrating a new chemotherapeutic agent, vinorelbine (Navelbine), into the current treatment regimens for patients with advanced-stage non-small-cell lung cancer. He reviews the phase II activity of